{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:13Z","timestamp":1790668513599,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of the Pacific at Stockton"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01281-4","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:44:46Z","timestamp":1788889486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Cannabidiol Pharmacokinetics in Older Adults Via Physiologically Based Pharmacokinetic Modeling"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-5529","authenticated-orcid":false,"given":"Lixuan","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6159-039X","authenticated-orcid":false,"given":"Aiden-Hung P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-1839","authenticated-orcid":false,"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2051-2239","authenticated-orcid":false,"given":"Zhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1281_CR1","unstructured":"Agriculture Improvement Act of 2018, Pub. L. No. 115\u2013334, 132 Stat. 4490 (Dec. 20, 2018).\u00a0https:\/\/www.congress.gov\/115\/plaws\/publ334\/PLAW-115publ334.pdf"},{"key":"1281_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040484","author":"L Qian","year":"2024","unstructured":"Qian L, Beers JL, Jackson KD, Zhou Z. CBD and THC in special populations: pharmacokinetics and drug-drug interactions. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16040484.","journal-title":"Pharmaceutics"},{"key":"1281_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1403147","volume":"15","author":"A Yndart Arias","year":"2024","unstructured":"Yndart Arias A, Vadell K, Vashist A, Kolishetti N, Lakshmana MK, Nair M, et al. Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials. Front Pharmacol. 2024;15:1403147.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1281_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.29768","volume":"39","author":"Y Liu","year":"2024","unstructured":"Liu Y, Bainbridge J, Sillau S, Rajkovic S, Adkins M, Domen CH, et al. Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson\u2019s Disease: A Randomized Trial. Mov Disord. 2024;39(5):863\u201375.","journal-title":"Mov Disord"},{"key":"1281_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/SAR.S375653","volume":"15","author":"J Hu","year":"2024","unstructured":"Hu J, Kulkarni N, Maliha P, Grossberg G. Prevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood. Subst Abuse Rehabil. 2024;15:87\u201398.","journal-title":"Subst Abuse Rehabil"},{"key":"1281_CR6","doi-asserted-by":"publisher","first-page":"100289","DOI":"10.1016\/j.dadr.2024.100289","volume":"13","author":"NG Choi","year":"2024","unstructured":"Choi NG, Marti CN, Choi BY. Prevalence of cannabidiol use and correlates in U.S. adults. Drug Alcohol Depend Rep. 2024;13:100289.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"10","key":"1281_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jcph.2299","volume":"63","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Slattum PW, Ke A, Zhang L. Managing Drug-Drug Interactions in Older Adults. J Clin Pharmacol. 2023;63(10):1083\u201390.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1281_CR8","doi-asserted-by":"publisher","first-page":"e70119","DOI":"10.1111\/cts.70119","volume":"18","author":"L Qian","year":"2025","unstructured":"Qian L, Zhang T, Dinh J, Paine MF, Zhou Z. Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta-9-Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes. Clin Transl Sci. 2025;18(1):e70119.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1281_CR9","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.molpharmaceut.5c01755","volume":"23","author":"F Harder","year":"2026","unstructured":"Harder F, Brouwers J, Vanuytsel T, Oswald S, Augustijns P. Advanced age-related changes in intestinal drug transporters and metabolising enzymes: a targeted proteomics study. Mol Pharm. 2026;23(5):2935\u201343.","journal-title":"Mol Pharm"},{"key":"1281_CR10","doi-asserted-by":"publisher","first-page":"1143835","DOI":"10.3389\/fendo.2023.1143835","volume":"14","author":"M Konstandi","year":"2023","unstructured":"Konstandi M, Johnson EO. Age-related modifications in CYP-dependent drug metabolism: role of stress. Front Endocrinol (Lausanne). 2023;14:1143835.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1281_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1124\/dmd.122.001128","volume":"51","author":"S Bansal","year":"2023","unstructured":"Bansal S, Ladumor MK, Paine MF, Unadkat JD. A physiologically-based pharmacokinetic model for cannabidiol in healthy adults, hepatically-impaired adults, and children. Drug Metab Dispos. 2023;51(6):743\u201352.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1281_CR12","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1124\/dmd.109.026898","volume":"37","author":"A Mazur","year":"2009","unstructured":"Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37(7):1496\u2013504.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1281_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1124\/dmd.120.000350","volume":"49","author":"JL Beers","year":"2021","unstructured":"Beers JL, Fu D, Jackson KD. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol. Drug Metab Dispos. 2021;49(10):882\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1281_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/psp4.12908","volume":"12","author":"CHT Yeung","year":"2023","unstructured":"Yeung CHT, Beers JL, Jackson KD, Edginton AN. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):320\u201332.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1281_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.tiv.2016.11.015","volume":"39","author":"M Vollmer","year":"2017","unstructured":"Vollmer M, Klingebiel M, Rohn S, Maul R. Alamethicin for using in bioavailability studies? - Re-evaluation of its effect. Toxicol In Vitro. 2017;39:111\u20138.","journal-title":"Toxicol In Vitro"},{"issue":"5","key":"1281_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1124\/dmd.111.043117","volume":"40","author":"RL Walsky","year":"2012","unstructured":"Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, et al. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos. 2012;40(5):1051\u201365.","journal-title":"Drug Metab Dispos"},{"key":"1281_CR17","doi-asserted-by":"publisher","unstructured":"Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. The National Academies Collection: Reports funded by National Institutes of Health. Washington, DC. 1997.\u00a0https:\/\/doi.org\/10.17226\/5776","DOI":"10.17226\/5776"},{"issue":"4","key":"1281_CR18","first-page":"S194","volume":"23","author":"RJ Elin","year":"2010","unstructured":"Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res. 2010;23(4):S194\u20138.","journal-title":"Magnes Res"},{"issue":"9","key":"1281_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.euroneuro.2014.06.007","volume":"24","author":"AI Ahmed","year":"2014","unstructured":"Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, et al. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24(9):1475\u201382.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"1281_CR20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1124\/dmd.115.065987","volume":"43","author":"G Li","year":"2015","unstructured":"Li G, Huang K, Nikolic D, van Breemen RB. High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions. Drug Metab Dispos. 2015;43(11):1670\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1281_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105810","volume":"162","author":"H Kahma","year":"2021","unstructured":"Kahma H, Aurinsalo L, Neuvonen M, Katajamaki J, Paludetto MN, Viinamaki J, et al. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity. Eur J Pharm Sci. 2021;162:105810.","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"1281_CR22","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1124\/dmd.114.059451","volume":"42","author":"BT Gufford","year":"2014","unstructured":"Gufford BT, Chen G, Lazarus P, Graf TN, Oberlies NH, Paine MF. Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation. Drug Metab Dispos. 2014;42(10):1675\u201383.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1281_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/2193-1801-2-236","volume":"2","author":"C Stott","year":"2013","unstructured":"Stott C, White L, Wright S, Wilbraham D, Guy G. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC\/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2(1):236.","journal-title":"Springerplus"},{"issue":"2","key":"1281_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/bms.1200130206","volume":"13","author":"A Ohlsson","year":"1986","unstructured":"Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 1986;13(2):77\u201383.","journal-title":"Biomed Environ Mass Spectrom"},{"issue":"1","key":"1281_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000489034","volume":"1","author":"P Meyer","year":"2018","unstructured":"Meyer P, Langos M, Brenneisen R. Human pharmacokinetics and adverse effects of pulmonary and intravenous THC-CBD formulations. Med Cannabis Cannabinoids. 2018;1(1):36\u201343.","journal-title":"Med Cannabis Cannabinoids"},{"issue":"5","key":"1281_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","volume":"69","author":"CG Stott","year":"2013","unstructured":"Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray. Eur J Clin Pharmacol. 2013;69(5):1135\u201347.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1281_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs. 2018;32(11):1053\u201367.","journal-title":"CNS Drugs"},{"issue":"8","key":"1281_CR28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/jcph.1412","volume":"59","author":"L Taylor","year":"2019","unstructured":"Taylor L, Crockett J, Tayo B, Morrison G. A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol. 2019;59(8):1110\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1281_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/epi.16419","volume":"61","author":"J Crockett","year":"2020","unstructured":"Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020;61(2):267\u201377.","journal-title":"Epilepsia"},{"issue":"5","key":"1281_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s13318-020-00624-6","volume":"45","author":"D Perkins","year":"2020","unstructured":"Perkins D, Butler J, Ong K, Nguyen TH, Cox S, Francis B, et al. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2020;45(5):575\u201386.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"1281_CR31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cpdd.665","volume":"8","author":"G Morrison","year":"2019","unstructured":"Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8(8):1009\u201331.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"1281_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/dmd.120.000322","volume":"49","author":"GI Patilea-Vrana","year":"2021","unstructured":"Patilea-Vrana GI, Unadkat JD. Development and Verification of a Linked Delta (9)-THC\/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. Drug Metab Dispos. 2021;49(7):509\u201320.","journal-title":"Drug Metab Dispos"},{"key":"1281_CR33","doi-asserted-by":"crossref","unstructured":"Qian L, Zhou Z. Using a PBPK Model Incorporating Lymphatic Absorption to Predict Food Effect, Multiple Dosing, and Hepatic Impairment of Cannabidiol. Clin Transl Sci. 2025;18(11):e70401.","DOI":"10.1111\/cts.70401"},{"issue":"11","key":"1281_CR34","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos. 2015;43(11):1823\u201337.","journal-title":"Drug Metab Dispos"},{"key":"1281_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162\u201371.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1281_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.arthro.2022.08.020","volume":"39","author":"JD Harris","year":"2023","unstructured":"Harris JD, Brand JC, Cote M, Waterman B, Dhawan A. Guidelines for Proper Reporting of Clinical Significance, Including Minimal Clinically Important Difference, Patient Acceptable Symptomatic State, Substantial Clinical Benefit, and Maximal Outcome Improvement. Arthroscopy. 2023;39(2):145\u201350.","journal-title":"Arthroscopy"},{"issue":"10","key":"1281_CR37","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1124\/dmd.120.000073","volume":"48","author":"S Bansal","year":"2020","unstructured":"Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. Drug Metab Dispos. 2020;48(10):1008\u201317.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1281_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0090-9556(24)15100-8","volume":"28","author":"MB Fisher","year":"2000","unstructured":"Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos. 2000;28(5):560\u20136.","journal-title":"Drug Metab Dispos"},{"key":"1281_CR39","doi-asserted-by":"publisher","first-page":"113916","DOI":"10.1016\/j.bcp.2020.113916","volume":"175","author":"K Ondo","year":"2020","unstructured":"Ondo K, Arakawa H, Nakano M, Fukami T, Nakajima M. SLC35B1 significantly contributes to the uptake of UDPGA into the endoplasmic reticulum for glucuronidation catalyzed by UDP-glucuronosyltransferases. Biochem Pharmacol. 2020;175:113916.","journal-title":"Biochem Pharmacol"},{"issue":"3\u20134","key":"1281_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1081\/DMR-120000653","volume":"33","author":"MB Fisher","year":"2001","unstructured":"Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev. 2001;33(3\u20134):273\u201397.","journal-title":"Drug Metab Rev"},{"issue":"9","key":"1281_CR41","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/00498254.2017.1376260","volume":"48","author":"G Walia","year":"2018","unstructured":"Walia G, Smith AD, Riches Z, Collier AC, Coughtrie MWH. The effects of UDP-sugars, UDP and Mg(2+)on uridine diphosphate glucuronosyltransferase activity in human liver microsomes. Xenobiotica. 2018;48(9):882\u201390.","journal-title":"Xenobiotica"},{"issue":"7","key":"1281_CR42","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.21037\/qims-21-227","volume":"11","author":"YXJ Wang","year":"2021","unstructured":"Wang YXJ. Gender-specific liver aging and magnetic resonance imaging. Quant Imaging Med Surg. 2021;11(7):2893\u2013904.","journal-title":"Quant Imaging Med Surg"},{"issue":"2","key":"1281_CR43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/bcp.70284","volume":"92","author":"IK Storgaard","year":"2026","unstructured":"Storgaard IK, Nielsen RL, Houlind MB, Bornaes O, Christensen LWS, Andersen AL, et al. Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Delta(9)-tetrahydrocannabinol in older patients with poor appetite. Br J Clin Pharmacol. 2026;92(2):504\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1281_CR44","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1111\/jocd.15427","volume":"21","author":"AK Gupta","year":"2022","unstructured":"Gupta AK, Talukder M. A cannabinoid Hairy-Tale: Hair loss or hair gain? J Cosmet Dermatol. 2022;21(12):6653\u201360.","journal-title":"J Cosmet Dermatol"},{"key":"1281_CR45","doi-asserted-by":"publisher","unstructured":"Ammendolia I, Mannucci C, Cardia L, Calapai G, Gangemi S, Esposito E, et al. Pharmacovigilance on cannabidiol as an antiepileptic agent. Front Pharmacol. 2023;14:1091978.\u00a0https:\/\/doi.org\/10.3389\/fphar.2023.1091978","DOI":"10.3389\/fphar.2023.1091978"},{"issue":"2","key":"1281_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/dmd.110.036103","volume":"39","author":"EJ Guest","year":"2011","unstructured":"Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39(2):170\u20133.","journal-title":"Drug Metab Dispos"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01281-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:19Z","timestamp":1790665339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01281-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01281-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F.P. and Z.Z are consultants for Delphian Therapeutics, Inc. All other authors declared no competing interests for this work.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"135"}}